A Study to Assess the Safety and Efficacy of a New Influenza Candidate Vaccine MVA-NP+M1 In Healthy Adults

Inclusion Criteria: 1. Male or females aged 18 - 45 years 2. HI titre of less than 10 3. In general good health determined by a screening evaluation (medical history, physical examination, vital signs electrocardiogram (ECG) and clinical safety laboratory tests). ECG and spirometry will be performed at entry into quarantine rather than at screening visit 4. Females should fulfil the following criteria: (i) not pregnant or breastfeeding for the duration of the study and (ii) agree to use a reliable form of contraception for the duration of the study if sexually active 5. Negative HBsAg, HIV and HCV antibody screen 6. Negative class A drugs of abuse screen 7. Have not been vaccinated for Influenza virus in the current season or had a known influenza virus infection in the current season 8. Give written informed consent to participate 9. Willingness to remain in isolation during the challenge phase of the study and to comply with all study requirements 10. Willing and able to communicate with the Investigator and understand the requirements of the study Exclusion Criteria: 1. Participation in another research study involving an investigational product in the 30 days preceding enrolment, or planned use of an IMP during the study period 2. Prior receipt of a recombinant MVA vaccine (vaccinees only) 3. Administration of immunoglobulins and/or any blood products within the three months preceding date of enrolment. 4. Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months 5. History of allergic disease or reactions likely to be exacerbated by any component of the vaccine, e.g. egg products. Any allergy to eggs or egg products 6. Any history of anaphylaxis in reaction to vaccination 7. Current cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ) 8. Serious current psychiatric condition 9. Any other chronic illness requiring hospital specialist supervision 10. Suspected or known current injecting drug or alcohol abuse (as defined by an alcohol intake of greater than 42 units every week) 11. Any other significant disease, disorder or finding, which, in the opinion of the Investigators, may either put the volunteer at risk because of participation in the study, or may influence the result of the study, or the volunteer's ability to participate in the study. 12. Any clinically significant abnormal finding on screening biochemistry or haematology blood tests or urinalysis (see Table 1. Values outside the stated limits of Table 1 need written comment by a physician if considered clinically insignificant). 13. Venous access inadequate for phlebotomy demands of the study 14. Clinically significant abnormality on ECG 15. History since age 13 of asthma of any aetiology 16. Smokers who are unwilling or unable to desist for the duration of the inpatient challenge component of the study 17. Any anatomic or neurologic abnormality impairing the gag reflex or associated with a risk of aspiration 18. Presence of febrile illness or symptoms of upper respiratory tract infection on the day of vaccination (vaccination would be deferred) 19. Presence of febrile illness or symptoms suggestive of influenza between admission for influenza challenge and administration of the challenge inoculum 20. Use of inhaled, topical or systemic steroids in the six months preceding date of enrolment other than occasional use of cutaneous steroid if considered clinically irrelevant to the study by the Investigator.. 21. Donation of blood or blood products within 7 days before study entry or at any time during the study 22. Donation of plasma within 7 days of study entry 23. Anti-'flu antibody titre of 10 or greater